Arcus Biosciences (RCUS) Revenue (2017 - 2026)

Arcus Biosciences has reported Revenue for 10 years, with the latest figure at $17.0 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 39.29% year-over-year to $17.0 million; the trailing twelve-month figure through Mar 2026 stood at $236.0 million (up 67.38% YoY), and the FY2025 full-year result was $247.0 million, down 4.26% from the prior year.
• Revenue for Q1 2026 stood at $17.0 million, down from $33.0 million in the prior quarter.
• The five-year high for Revenue was $160.0 million in Q2 2025, with the low at $14.0 million in Q4 2023.
• Average Revenue over 5 years is $43.2 million, with a median of $29.0 million recorded in 2023.
• Year-over-year, Revenue slumped 90.41% in 2022 and soared 480.0% in 2024.
• Tracing RCUS's Revenue over 5 years: stood at $34.0 million in 2022, then tumbled by 58.82% to $14.0 million in 2023, then soared by 85.71% to $26.0 million in 2024, then advanced by 26.92% to $33.0 million in 2025, then tumbled by 48.48% to $17.0 million in 2026.
• The last three Revenue figures came in at $17.0 million (Q1 2026), $33.0 million (Q4 2025), and $26.0 million (Q3 2025), per Business Quant data.

Peer Comparison